vs
Side-by-side financial comparison of CARPENTER TECHNOLOGY CORP (CRS) and HALOZYME THERAPEUTICS, INC. (HALO). Click either name above to swap in a different company.
CARPENTER TECHNOLOGY CORP is the larger business by last-quarter revenue ($728.0M vs $451.8M, roughly 1.6× HALOZYME THERAPEUTICS, INC.). CARPENTER TECHNOLOGY CORP runs the higher net margin — 14.5% vs -31.3%, a 45.8% gap on every dollar of revenue. On growth, HALOZYME THERAPEUTICS, INC. posted the faster year-over-year revenue change (51.6% vs 7.5%). HALOZYME THERAPEUTICS, INC. produced more free cash flow last quarter ($217.6M vs $85.9M). Over the past eight quarters, HALOZYME THERAPEUTICS, INC.'s revenue compounded faster (51.9% CAGR vs 3.1%).
Carpenter Technology Corporation develops, manufactures, and distributes stainless steels and corrosion-resistant nickel, copper and titanium alloys as well as powdered alloys for 3D additive manufacturing. In fiscal year 2018, the company's revenues were derived from the aerospace and defense industry (55%), the industrial and consumer industry (17%), the medical industry (8%), the transportation industry (7%), the energy industry (7%), and the distribution industry (6%). The company's produ...
Halozyme Therapeutics, Inc. is an American biotechnology company. It develops oncology therapies designed to target the tumor microenvironment.
CRS vs HALO — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $728.0M | $451.8M |
| Net Profit | $105.3M | $-141.6M |
| Gross Margin | 30.0% | 82.6% |
| Operating Margin | 21.3% | -20.6% |
| Net Margin | 14.5% | -31.3% |
| Revenue YoY | 7.5% | 51.6% |
| Net Profit YoY | 25.2% | -203.3% |
| EPS (diluted) | $2.09 | $-1.13 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $728.0M | $451.8M | ||
| Q3 25 | $733.7M | $354.3M | ||
| Q2 25 | $755.6M | $325.7M | ||
| Q1 25 | $727.0M | $264.9M | ||
| Q4 24 | $676.9M | $298.0M | ||
| Q3 24 | $717.6M | $290.1M | ||
| Q2 24 | $798.7M | $231.4M | ||
| Q1 24 | $684.9M | $195.9M |
| Q4 25 | $105.3M | $-141.6M | ||
| Q3 25 | $122.5M | $175.2M | ||
| Q2 25 | $111.7M | $165.2M | ||
| Q1 25 | $95.4M | $118.1M | ||
| Q4 24 | $84.1M | $137.0M | ||
| Q3 24 | $84.8M | $137.0M | ||
| Q2 24 | $93.6M | $93.2M | ||
| Q1 24 | $6.3M | $76.8M |
| Q4 25 | 30.0% | 82.6% | ||
| Q3 25 | 29.5% | 84.4% | ||
| Q2 25 | 28.3% | 85.8% | ||
| Q1 25 | 27.6% | 81.7% | ||
| Q4 24 | 26.2% | 85.9% | ||
| Q3 24 | 24.6% | 83.0% | ||
| Q2 24 | 23.9% | 82.9% | ||
| Q1 24 | 21.5% | 85.5% |
| Q4 25 | 21.3% | -20.6% | ||
| Q3 25 | 20.9% | 61.5% | ||
| Q2 25 | 20.1% | 62.2% | ||
| Q1 25 | 19.0% | 53.4% | ||
| Q4 24 | 17.6% | 58.9% | ||
| Q3 24 | 15.8% | 56.3% | ||
| Q2 24 | 13.6% | 50.7% | ||
| Q1 24 | 11.1% | 48.8% |
| Q4 25 | 14.5% | -31.3% | ||
| Q3 25 | 16.7% | 49.5% | ||
| Q2 25 | 14.8% | 50.7% | ||
| Q1 25 | 13.1% | 44.6% | ||
| Q4 24 | 12.4% | 46.0% | ||
| Q3 24 | 11.8% | 47.2% | ||
| Q2 24 | 11.7% | 40.3% | ||
| Q1 24 | 0.9% | 39.2% |
| Q4 25 | $2.09 | $-1.13 | ||
| Q3 25 | $2.43 | $1.43 | ||
| Q2 25 | $2.21 | $1.33 | ||
| Q1 25 | $1.88 | $0.93 | ||
| Q4 24 | $1.66 | $1.06 | ||
| Q3 24 | $1.67 | $1.05 | ||
| Q2 24 | $1.85 | $0.72 | ||
| Q1 24 | $0.12 | $0.60 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $231.9M | $133.8M |
| Total DebtLower is stronger | — | $2.1B |
| Stockholders' EquityBook value | $2.0B | $48.8M |
| Total Assets | $3.5B | $2.5B |
| Debt / EquityLower = less leverage | — | 43.89× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $231.9M | $133.8M | ||
| Q3 25 | $208.0M | $419.7M | ||
| Q2 25 | $315.5M | $61.9M | ||
| Q1 25 | $151.5M | $176.3M | ||
| Q4 24 | $162.1M | $115.8M | ||
| Q3 24 | $150.2M | $154.3M | ||
| Q2 24 | $199.1M | $187.9M | ||
| Q1 24 | $53.5M | $164.6M |
| Q4 25 | — | $2.1B | ||
| Q3 25 | — | $1.5B | ||
| Q2 25 | — | $1.5B | ||
| Q1 25 | — | $1.5B | ||
| Q4 24 | — | $1.5B | ||
| Q3 24 | — | $1.5B | ||
| Q2 24 | — | $1.5B | ||
| Q1 24 | — | $1.5B |
| Q4 25 | $2.0B | $48.8M | ||
| Q3 25 | $1.9B | $503.9M | ||
| Q2 25 | $1.9B | $332.7M | ||
| Q1 25 | $1.8B | $482.3M | ||
| Q4 24 | $1.7B | $363.8M | ||
| Q3 24 | $1.7B | $452.7M | ||
| Q2 24 | $1.6B | $289.4M | ||
| Q1 24 | $1.5B | $177.8M |
| Q4 25 | $3.5B | $2.5B | ||
| Q3 25 | $3.4B | $2.2B | ||
| Q2 25 | $3.5B | $2.1B | ||
| Q1 25 | $3.4B | $2.2B | ||
| Q4 24 | $3.3B | $2.1B | ||
| Q3 24 | $3.3B | $2.1B | ||
| Q2 24 | $3.3B | $2.0B | ||
| Q1 24 | $3.2B | $1.8B |
| Q4 25 | — | 43.89× | ||
| Q3 25 | — | 3.00× | ||
| Q2 25 | — | 4.54× | ||
| Q1 25 | — | 3.13× | ||
| Q4 24 | — | 4.14× | ||
| Q3 24 | — | 3.32× | ||
| Q2 24 | — | 5.19× | ||
| Q1 24 | — | 8.44× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $132.2M | $219.0M |
| Free Cash FlowOCF − Capex | $85.9M | $217.6M |
| FCF MarginFCF / Revenue | 11.8% | 48.2% |
| Capex IntensityCapex / Revenue | 6.4% | 0.3% |
| Cash ConversionOCF / Net Profit | 1.26× | — |
| TTM Free Cash FlowTrailing 4 quarters | $316.7M | $644.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $132.2M | $219.0M | ||
| Q3 25 | $39.2M | $178.6M | ||
| Q2 25 | $258.1M | $99.7M | ||
| Q1 25 | $74.2M | $154.2M | ||
| Q4 24 | $67.9M | $178.5M | ||
| Q3 24 | $40.2M | $115.4M | ||
| Q2 24 | $169.5M | $55.8M | ||
| Q1 24 | $83.5M | $129.4M |
| Q4 25 | $85.9M | $217.6M | ||
| Q3 25 | $-3.4M | $175.6M | ||
| Q2 25 | $200.2M | $98.1M | ||
| Q1 25 | $34.0M | $153.3M | ||
| Q4 24 | $38.6M | $175.4M | ||
| Q3 24 | $13.3M | $113.9M | ||
| Q2 24 | $141.8M | $53.2M | ||
| Q1 24 | $61.9M | $125.9M |
| Q4 25 | 11.8% | 48.2% | ||
| Q3 25 | -0.5% | 49.6% | ||
| Q2 25 | 26.5% | 30.1% | ||
| Q1 25 | 4.7% | 57.9% | ||
| Q4 24 | 5.7% | 58.9% | ||
| Q3 24 | 1.9% | 39.3% | ||
| Q2 24 | 17.8% | 23.0% | ||
| Q1 24 | 9.0% | 64.3% |
| Q4 25 | 6.4% | 0.3% | ||
| Q3 25 | 5.8% | 0.9% | ||
| Q2 25 | 7.7% | 0.5% | ||
| Q1 25 | 5.5% | 0.4% | ||
| Q4 24 | 4.3% | 1.0% | ||
| Q3 24 | 3.7% | 0.5% | ||
| Q2 24 | 3.5% | 1.1% | ||
| Q1 24 | 3.2% | 1.8% |
| Q4 25 | 1.26× | — | ||
| Q3 25 | 0.32× | 1.02× | ||
| Q2 25 | 2.31× | 0.60× | ||
| Q1 25 | 0.78× | 1.31× | ||
| Q4 24 | 0.81× | 1.30× | ||
| Q3 24 | 0.47× | 0.84× | ||
| Q2 24 | 1.81× | 0.60× | ||
| Q1 24 | 13.25× | 1.68× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CRS
| Aerospace And Defense Markets | $448.8M | 62% |
| Industrial And Consumer Markets | $88.4M | 12% |
| Performance Engineered Products Segment | $83.2M | 11% |
| Medical Market | $54.7M | 8% |
| Energy Market | $48.5M | 7% |
| Transportation Market | $21.2M | 3% |
| Distribution Market | $17.2M | 2% |
HALO
| Royalty | $258.0M | 57% |
| Products | $122.7M | 27% |
| Proprietary Products Sales | $59.6M | 13% |
| Device Partnered Products | $12.9M | 3% |
